Chenyu Lin, MD, Duke University Medical Center, Durham, NC, discusses the findings from a pooled analysis of a long-term follow-up of allogeneic stem cell transplantation (alloSCT) with omidubicel in patients with hematological malignancies. Dr Lin first explains the limitations of using stem cells derived from umbilical cord blood, and how ex-vivo expanded products such as omidubicel may overcome these limitations. Following this, Dr Lin discusses the results from a recent pooled analysis of five prospective clinical trials which evaluated the long-term outcomes of omidubicel transplantation in patients with various hematological malignancies, commenting on the graft durability, overall survival (OS), and adverse events (AEs) observed. To conclude, Dr Lin discusses the patient-reported quality of life with omidubicel, and further comments on the potential approval of this agent by the FDA in the near future. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.